受惠ZOOM股價向上 李嘉誠重登福布斯香港首富
福布斯公布香港富豪榜,去年香港經濟收縮6.1%,是1998年以來最差,不過恆指升勢帶動香港50名首富身家進帳3,310億美元,升幅達7.5%。
李嘉誠重奪香港首富地位,身家升20%至354億美元,雖然期內長實集團(01113.HK)股價跌27%,但他持有的ZOOM(ZM.US)股價大升,帶動身家跑贏第二位的李兆基,鄭家純家族則排名第三。
而今年身家升幅最大的是伯恩光學創辦人楊建文夫婦,受惠智能手機玻璃需求增加,二人身家翻倍至186億美元,排名躍升至第四位。敏華控股(01999.HK)主席黃敏利身家亦升200%至63億美元,主要受惠旗下公司收入按年增長19%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.